Cover Image
市場調查報告書

男性不孕症的開發中產品分析

Male Infertility - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255962
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
男性不孕症的開發中產品分析 Male Infertility - Pipeline Review, H2 2015
出版日期: 2015年08月19日 內容資訊: 英文 44 Pages
簡介

所謂男性不孕症,是指男性方面沒有使可懷孕之正常女性懷孕的狀態。男性不孕症可因造精功能障礙或精子無力、射精障礙等原因造成。主要症狀有睪丸附近疼痛、紅朣、疙瘩等。主要致病原因有抽煙或喝酒、體重超重、曝露在毒素下、特定疾病(腫瘤·慢性病及其他)等。主要治療法有外科手術及荷爾蒙補充治療等。

本報告提供全球各國治療男性不孕症的開發中產品之開發情形分析,提供開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

男性不孕症概要

治療藥的開發

  • 男性不孕症開發中產品:概要
  • 男性不孕症開發中產品:比較分析

各企業正在開發的男性不孕症治療藥

大學/研究機關正在研究中的男性不孕症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

男性不孕症治療藥:開發中產品一覽(各企業)

男性不孕症治療藥:研究中產品一覽(大學/研究機關別)

參與男性不孕症治療藥開發的企業

  • Zydus Cadila Healthcare Limited
  • Access Pharmaceuticals, Inc.
  • Pantarhei Bioscience BV

男性不孕症:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各類型分子

藥物簡介

  • oxytocin+雌激素
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • isotretinoin
  • 急性心肌梗塞·不孕症生技仿製藥(4)
  • 口服妊娠促進藥
  • 不孕症FSH受體激動劑
  • 不孕症生技仿製藥(6)
  • 不孕症生技仿製藥(5)
  • 不孕症生技仿製藥(7)
  • 男性不孕症幹細胞治療

男性不孕症治療藥:暫停開發的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7009IDB

Summary

Global Markets Direct's, 'Male Infertility - Pipeline Review, H2 2015', provides an overview of the Male Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Male Infertility
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Male Infertility and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Male Infertility pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Male Infertility
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Male Infertility pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Male Infertility Overview
  • Therapeutics Development
    • Pipeline Products for Male Infertility - Overview
    • Pipeline Products for Male Infertility - Comparative Analysis
  • Male Infertility - Therapeutics under Development by Companies
  • Male Infertility - Therapeutics under Investigation by Universities/Institutes
  • Male Infertility - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Male Infertility - Products under Development by Companies
  • Male Infertility - Products under Investigation by Universities/Institutes
  • Male Infertility - Companies Involved in Therapeutics Development
    • AlphaMab Co., Ltd
    • Ferring International Center S.A.
    • Pantarhei Bioscience BV
    • PharmaEssentia Corporation
    • Zydus Cadila Healthcare Limited
  • Male Infertility - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (oxytocin + estrogen) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 5 for Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 6 for Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 7 for Infertility and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FE-999310 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LM-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LM-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCS-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-FSH - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize FSHR for Infertility - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trequinsin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Male Infertility - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Male Infertility, H2 2015
  • Number of Products under Development for Male Infertility - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Male Infertility - Pipeline by AlphaMab Co., Ltd, H2 2015
  • Male Infertility - Pipeline by Ferring International Center S.A., H2 2015
  • Male Infertility - Pipeline by Pantarhei Bioscience BV, H2 2015
  • Male Infertility - Pipeline by PharmaEssentia Corporation, H2 2015
  • Male Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Male Infertility - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Male Infertility, H2 2015
  • Number of Products under Development for Male Infertility - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top